These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 25395481)

  • 21. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
    Chang KC; Yew WW
    Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
    Park S; Lee KM; Kim I; Mok J
    Int J Infect Dis; 2018 Nov; 76():88-90. PubMed ID: 30244076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
    Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
    Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study.
    Barilar I; Fernando T; Utpatel C; Abujate C; Madeira CM; José B; Mutaquiha C; Kranzer K; Niemann T; Ismael N; de Araujo L; Wirth T; Niemann S; Viegas S
    Lancet Infect Dis; 2024 Mar; 24(3):297-307. PubMed ID: 37956677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
    Muniyandi M; Ramachandran R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
    Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
    Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
    Tiberi S; De Lorenzo S; Centis R; Viggiani P; D'Ambrosio L; Migliori GB
    Eur Respir J; 2014 Jan; 43(1):289-92. PubMed ID: 23988772
    [No Abstract]   [Full Text] [Related]  

  • 33. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Epidemiology of drug-resistant tuberculosis: world--Europe--Poland].
    Jagielski T; Augustynowicz-Kopeć E; Zwolska Z
    Wiad Lek; 2010; 63(4):345-57. PubMed ID: 21612049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
    Gras J
    Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
    Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs.
    Sullivan T; Ben Amor Y
    Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26889711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
    Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.